ABSI
Price
$10.33
Change
+$0.64 (+6.60%)
Updated
Nov 3, 11:45 AM (EDT)
Capitalization
1.66B
9 days until earnings call
Intraday BUY SELL Signals
PRME
Price
$4.44
Change
-$0.28 (-5.93%)
Updated
Nov 2 closing price
Capitalization
805.31M
3 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABSI vs PRME

ABSI vs PRME Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABSI vs. PRME commentary
Nov 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABSI is a Buy and PRME is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ABSI with price predictions
Nov 02, 2026

ABSI in upward trend: price rose above 50-day moving average on October 26, 2026

ABSI moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend. In 46 of 51 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ABSI as a result. In 80 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.

The Moving Average Convergence Divergence (MACD) for ABSI just turned positive on October 27, 2026. Looking at past instances where ABSI's MACD turned positive, the stock continued to rise in 38 of 46 cases over the following month. The odds of a continued upward trend are 83%.

The 10-day moving average for ABSI crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.

Following a +14.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABSI advanced for three days, in 242 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

The Aroon Indicator entered an Uptrend today. In 147 of 175 cases where ABSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.

Bearish Trend Analysis

The 10-day RSI Indicator for ABSI moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 23 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 58 cases where ABSI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

ABSI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ABSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 70 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.756) is normal, around the industry mean (3.104). P/E Ratio (-12.266) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (769.231) is also within normal values, averaging (439.647).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for PRME with price predictions
Nov 02, 2026

Aroon Indicator for PRME shows an upward move is likely

PRME's Aroon Indicator triggered a bullish signal on November 02, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 114 similar instances where the Aroon Indicator showed a similar pattern. In 98 of the 114 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on PRME as a result. In 51 of 64 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for PRME just turned positive on October 06, 2026. Looking at past instances where PRME's MACD turned positive, the stock continued to rise in 29 of 35 cases over the following month. The odds of a continued upward trend are 83%.

PRME moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PRME crossed bullishly above the 50-day moving average on October 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.

Following a +48.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRME advanced for three days, in 159 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The 10-day RSI Indicator for PRME moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 16 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 40 cases where PRME's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

PRME broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.403) is normal, around the industry mean (3.104). P/E Ratio (-4.229) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PRME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
PRME: Fundamental Ratings
PRME
OUTLOOK RATING
1..100
80
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
87
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABSIPRME
RSI
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 6 days ago
90%
Bullish Trend 7 days ago
82%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
86%
COMPARISON
Comparison
Nov 03, 2026
Stock price -- (ABSI: $9.69 vs. PRME: $4.44)
Brand notoriety: ABSI and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABSI: 87% vs. PRME: 83%
Market capitalization -- ABSI: $1.66B vs. PRME: $805.31M
ABSI [@Biotechnology] is valued at $1.66B. PRME’s [@Biotechnology] market capitalization is $805.31M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $140.2B. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABSI’s FA Score shows that 0 FA rating(s) are green while PRME’s FA Score has 1 green FA rating(s).

  • ABSI’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 1 green, 4 red.
According to our system of comparison, PRME is a better buy in the long-term than ABSI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABSI’s TA Score shows that 6 TA indicator(s) are bullish while PRME’s TA Score has 6 bullish TA indicator(s).

  • ABSI’s TA Score: 6 bullish, 4 bearish.
  • PRME’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both ABSI and PRME are a good buy in the short-term.

Price Growth

ABSI (@Biotechnology) experienced а +2.54% price change this week, while PRME (@Biotechnology) price change was +22.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.94%. For the same industry, the average monthly price growth was -11.98%, and the average quarterly price growth was -17.06%.

Reported Earning Dates

ABSI is expected to report earnings on Nov 12, 2026.

PRME is expected to report earnings on Nov 06, 2026.

Industries' Descriptions

@Biotechnology (-1.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ABSI
Daily Signal:
Gain/Loss:
PRME
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-5.93%
CRSP - PRME
66%
Loosely correlated
-2.78%
BEAM - PRME
64%
Loosely correlated
-4.99%
RXRX - PRME
62%
Loosely correlated
-4.96%
EDIT - PRME
62%
Loosely correlated
-3.75%
RCKT - PRME
55%
Loosely correlated
+1.23%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SEGG1.930.60
+45.11%
Sports Entertainment Gaming Global Corporation
TIPT17.590.55
+3.23%
Tiptree
LNT73.021.37
+1.91%
Alliant Energy Corp
OSS4.83-0.31
-6.03%
One Stop Systems
AXTI48.20-6.86
-12.46%
AXT